����������

The Infectious Diseases Clinical Research Consortium has begun enrolling up to 1,000 pregnant and postpartum individuals who have or will receive COVID-19 vaccine in a study to assess vaccine safety, immune response and transfer of antibodies to their infants, the National Institutes of Health  yesterday. The study will enroll individuals up to two months postpartum, and follow participants and their infants through the first year after delivery.

“Tens of thousands of pregnant and breastfeeding people in the United States have chosen to receive the COVID-19 vaccines available under emergency use authorization,” said Anthony Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases “However, we lack robust, prospective clinical data on vaccination in these populations. The results of this study will fill gaps in our knowledge and help inform policy recommendations and personal decision-making on COVID-19 vaccination during pregnancy and in the postpartum period.”